Biotech Tracker
ConferenceAug 2026a window, not a day

Repatha VESALIUS-CV new analyses as oral abstracts at ESC Congress 2026

Amgen presented data on Repatha (evolocumab) for Primary prevention of cardiovascular events (VESALIUS-CV) at a medical meeting in Aug 2026. The linked source has the details.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsData presented at a medical meeting
Company
Amgen Inc. AMGN
Drug
Repatha (evolocumab)
For
Primary prevention of cardiovascular events (VESALIUS-CV)
Stage
Phase 3 · the last stage before a drug can be approved
When
Aug 2026 · the company gave a window, not a day; the calendar never invents one
Source note
Amgen's Aug 4, 2026 Q2 release says three new pre-specified VESALIUS-CV analyses (total CV events, MI, fatal outcomes) will be presented as oral abstracts at ESC Congress in August 2026 (ESC 2026 runs late August).
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Amgen Inc.
AMGN
6 upcoming · 8 past catalysts
More from AMGN
MilestoneAMGNAmgen2026

Three MariTide Phase 3 studies in type 2 diabetes to start in 2026, expected during 2026 (no exact date yet). A company milestone for Amgen (MariTide (maridebart cafraglutide) for Type 2 diabetes): a step in the program rather than a decision or a data readout.

More details
Entry
Three MariTide Phase 3 studies in type 2 diabetes to start in 2026 · Company milestone
Drug
MariTide (maridebart cafraglutide)
For
Type 2 diabetes
Stage
Phase 3 · the last stage before a drug can be approved
When
2026 · the company gave a window, not a day
Source note
Q2 2026 release; source only says 'in 2026' so remaining 2026 window applies.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsAMGNAmgenH2 2026

Amgen expects to report results from its Phase 3 study of dazodalibep for Sjogren's disease (systemic and symptomatic Phase 3 studies) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Dazodalibep Phase 3 Sjogren's disease results · Clinical trial results (readout / topline data)
Drug
dazodalibep
For
Sjogren's disease (systemic and symptomatic Phase 3 studies)
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
On the Q2 2026 earnings call (Aug 4, 2026) Amgen said Phase 3 results from the systemic (621 patients) and symptomatic (434 patients) Sjogren's studies are 'expected later this year'.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ApprovalAMGNAmgenH2 2026

Amgen expects European regulators to decide on Repatha (evolocumab) for Broader use before a first heart attack or stroke (VESALIUS-CV label expansion) in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.

More details
Entry
EC decision on Repatha label expansion for primary prevention (VESALIUS-CV) · Regulatory approval
Drug
Repatha (evolocumab)
For
Broader use before a first heart attack or stroke (VESALIUS-CV label expansion)
Stage
Regulatory
When
H2 2026 · the company gave a window, not a day
Source note
July 29, 2026 PR announcing positive CHMP opinion; company only says EC decision expected 'in the coming months' (timing vague, mapped to 2026-H2). EC typically acts ~2 months after CHMP.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneAMGNAmgenH2 2026

TEZSPIRE Phase 3 eosinophilic esophagitis study completion, expected in the second half of 2026 (no exact date yet). A company milestone for Amgen (TEZSPIRE (tezepelumab) for Eosinophilic esophagitis): a step in the program rather than a decision or a data readout.

More details
Entry
TEZSPIRE Phase 3 eosinophilic esophagitis study completion · Company milestone
Drug
TEZSPIRE (tezepelumab)
For
Eosinophilic esophagitis
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
Q2 2026 release: 'A Phase 3 study of TEZSPIRE is ongoing in patients with eosinophilic esophagitis. Study completion is expected in H2 2026.' Note this is study completion, not an explicit topline-date guidance.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneAMGNAmgenH2 2026

UPLIZNA Phase 3 CIDP study initiation, expected in the second half of 2026 (no exact date yet). A company milestone for Amgen (UPLIZNA (inebilizumab) for Chronic inflammatory demyelinating polyneuropathy): a step in the program rather than a decision or a data readout.

More details
Entry
UPLIZNA Phase 3 CIDP study initiation · Company milestone
Drug
UPLIZNA (inebilizumab)
For
Chronic inflammatory demyelinating polyneuropathy
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
Q2 2026 release guides the CIDP Phase 3 start to an H2 2026 - H1 2027 window; dated to the start of that window.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsAMGNAmgenH1 2027

Amgen expects to report results from its Phase 3 study of MariTide (maridebart cafraglutide) for Chronic weight management in obesity/overweight (MARITIME-1) and obesity with Type 2 diabetes (MARITIME-2) in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
MariTide Phase 3 MARITIME-1 and MARITIME-2 obesity topline data · Clinical trial results (readout / topline data)
Drug
MariTide (maridebart cafraglutide)
For
Chronic weight management in obesity/overweight (MARITIME-1) and obesity with Type 2 diabetes (MARITIME-2)
Stage
Phase 3 · the last stage before a drug can be approved
When
H1 2027 · the company gave a window, not a day
Source note
Primary readouts of the 72-week MARITIME-1 (~3,500 participants) and MARITIME-2 (~999 participants) trials are reported to be expected at the start of 2027. Amgen itself has not press-released a precise readout date, calling 2026 'a year of very disciplined data generation'.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page